Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Long-Term Deferred Tax (2023 - 2025)

Historic Long-Term Deferred Tax for Ascendis Pharma A (ASND) over the last 3 years, with Q4 2025 value amounting to -$11.2 million.

  • Ascendis Pharma A's Long-Term Deferred Tax fell 4444.05% to -$11.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$11.2 million, marking a year-over-year decrease of 4444.05%. This contributed to the annual value of -$10.9 million for FY2025, which is 4021.61% down from last year.
  • As of Q4 2025, Ascendis Pharma A's Long-Term Deferred Tax stood at -$11.2 million, which was down 4444.05% from -$7.8 million recorded in Q4 2024.
  • Ascendis Pharma A's 5-year Long-Term Deferred Tax high stood at -$6.3 million for Q4 2023, and its period low was -$11.2 million during Q4 2025.
  • Its 3-year average for Long-Term Deferred Tax is -$8.4 million, with a median of -$7.8 million in 2024.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first crashed by 2364.42% in 2024, then tumbled by 4444.05% in 2025.
  • Quarter analysis of 3 years shows Ascendis Pharma A's Long-Term Deferred Tax stood at -$6.3 million in 2023, then fell by 23.64% to -$7.8 million in 2024, then crashed by 44.44% to -$11.2 million in 2025.
  • Its last three reported values are -$11.2 million in Q4 2025, -$7.8 million for Q4 2024, and -$6.3 million during Q4 2023.